Janssen Reports Results of Ponesimod in P-III OPTIMUM Study for

Shots: The P-III OPTIMUM study results involve assessing of Ponesimod (20 mg) vs Aubagio (teriflunomide, 14mg) in 1,133 patients with relapsing MS for 108wks. at 162 sites across the globe The P-III OPTIMUM study results: 30.5% reduction in ARR (0.202 vs 0.290); 56% reduction in the number of CUALs; @12wks. CDA (10.1% vs 12.4%); safety […]Read More